- Home
- BWLP vs VRDN Comparison
BWLP vs VRDN Comparison
Compare BWLP & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWLP
- VRDN
- Stock Information
- Founded
- BWLP 1935
- VRDN 2006
- Country
- BWLP Singapore
- VRDN United States
- Employees
- BWLP N/A
- VRDN N/A
- Industry
- BWLP Marine Transportation
- VRDN Medical Specialities
- Sector
- BWLP Consumer Discretionary
- VRDN Health Care
- Exchange
- BWLP Nasdaq
- VRDN Nasdaq
- Market Cap
- BWLP 1.6B
- VRDN 1.3B
- IPO Year
- BWLP N/A
- VRDN N/A
- Fundamental
- Price
- BWLP $14.77
- VRDN $16.41
- Analyst Decision
- BWLP
- VRDN Strong Buy
- Analyst Count
- BWLP 0
- VRDN 11
- Target Price
- BWLP N/A
- VRDN $38.80
- AVG Volume (30 Days)
- BWLP 322.0K
- VRDN 722.5K
- Earning Date
- BWLP 08-27-2025
- VRDN 08-06-2025
- Dividend Yield
- BWLP 11.50%
- VRDN N/A
- EPS Growth
- BWLP N/A
- VRDN N/A
- EPS
- BWLP 1.86
- VRDN N/A
- Revenue
- BWLP $3,387,328,000.00
- VRDN $305,000.00
- Revenue This Year
- BWLP N/A
- VRDN N/A
- Revenue Next Year
- BWLP N/A
- VRDN $17,102.33
- P/E Ratio
- BWLP $8.72
- VRDN N/A
- Revenue Growth
- BWLP 9.53
- VRDN 5.90
- 52 Week Low
- BWLP $7.86
- VRDN $9.90
- 52 Week High
- BWLP $16.82
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- BWLP 71.35
- VRDN 47.57
- Support Level
- BWLP $14.63
- VRDN $15.70
- Resistance Level
- BWLP $14.93
- VRDN $17.79
- Average True Range (ATR)
- BWLP 0.25
- VRDN 0.96
- MACD
- BWLP 0.07
- VRDN -0.18
- Stochastic Oscillator
- BWLP 82.08
- VRDN 23.40
About BWLP BW LPG Limited Common Shares
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).